Presentations and Publications

We share our latest data at medical conferences and around the world. This allows us to showcase our innovative approach to drug discovery and development.

We share our latest data at medical conferences and around the world. This allows us to showcase our innovative approach to drug discovery and development.

Sitravatinib
(MGCD516)
Adagrasib
(MRTX849)
Preclinical

Sitravatinib (MGCD516)

Presentation — ESMO 2021
MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Poster — ASCO GU 2021
Phase 1/1B Study of Sitravatinib + Nivolumab + Ipilimumab in Patients With Advanced Clear Cell Renal Cell Carcinoma (accRCC) and Potentially Other Solid Malignancies
Presentation — ASCO GU 2021
A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally Advanced Clear Cell Renal Cell Carcinoma
Presentation — ESMO 2020
Sitravatinib in Combination with Nivolumab Demonstrates Clinical Activity in Checkpoint Inhibitor-Naïve, Platinum-Experienced Patients with Advanced or Metastatic Urothelial Carcinoma (a/mUC)
Poster — ASCO 2020
Phase 3 Trial of Sitravatinib plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemotherapy and Immunotherapy (SAPPHIRE)
Poster — ASCO 2020
SNOW: Sitravatinib and Nivolumab in Oral Cavity Cancer Window of Opportunity Study
Presentation — ASCO GU 2020
A Phase 1-2 Trial of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cell Cancer that Progressed on Prior Anti-Angiogenic Therapy
Poster — SITC 2019
SNOW: Sitravatinib and Nivolumab in Oral Cavity Cancer Window of Opportunity Study
Presentation — SITC 2019
Sitravatinib + Nivolumab Demonstrates Clinical Activity in Platinum-Experienced Urothelial Carcinoma Patients Who Progressed on Prior Checkpoint Inhibitor
Poster — IASLC WCLC 2019
Phase 3 Trial of Sitravatinib plus Nivolumab vs Docetaxel for Treatment of NSCLC after Platinum-Based Chemoimmunotherapy
Poster — ASCO Genitourinary Cancers Symposium 2019
Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (UC) after Checkpoint Inhibitor Therapy (CIT)
Poster — ASCO Genitourinary Cancers Symposium 2019
Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Poster — SITC 2018
Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor
Presentation — ESMO 2018
Stage 2 Enrollment Complete: Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy
Presentation — ESMO 2018
Sitravatinib Demonst/wp-content/uploads/2020/02/20180921_ESMO-2018-MRTX-500-Stage-2-Enrollment-Complete-Sitravatinib-in-Combination-witrates Activity in Patients with Novel Genetic Alterations that Inactivate CBL
Poster — ASCO 2018
Evaluation of the spectrum selective RTK inhibitor in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy
Presentation — World Conference on Lung Cancer 2017
Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy
Poster — World Conference on Lung Cancer 2017
CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
Poster — IASLC 2017 CHICAGO
CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
Poster — IASLC 2016
A study of MGCD516, a receptor tyrosine kinase (RTK) inhibitor, in molecularly selected patients with NSCLC or other advanced solid tumors
Poster — IASLC 2016
Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
Poster — ASCO 2016
A First-in-Human Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor MGCD516 in Patients with Advanced Solid Tumors

Adagrasib (MRTX849)

Presentation — ESMO 2021
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
Poster — ESMO GI 2021
KRYSTAL-10: A Randomized Phase 3 Study of Adagrasib (MRTX849) in Combination With Cetuximab vs Chemotherapy in Patients (Pts) With Previously Treated Advanced Colorectal Cancer (CRC) With KRASG12C Mutation
Poster — ASCO 2021
KRYSTAL-12: A Randomized Phase 3 Study of Adagrasib (MRTX849) vs Docetaxel in Patients With Previously Treated Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation
Presentation — ELCC 2021
KRYSTAL-1: Activity and Preliminary Pharmacodynamic (PD) Analysis of Adagrasib (MRTX849) in Patients (PTS) With Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring KRASG12C Mutation
Poster — ASCO GI 2021
KRYSTAL-2 (849-002): Phase 1/2, Open-Label, Multiple-Expansion-Cohort Trial of Adagrasib (MRTX849) + TNO155 (SHP2 Inhibitor) in KRASG12C Solid Tumors
Poster — WCLC 2020
KRYSTAL-7: A Phase 2 Trial of Adagrasib (MRTX849) With Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation
Presentation — EORTC-NCI-AACR 32nd Symposium 2020
KRYSTAL-1: Updated Safety and Efficacy Data With Adagrasib (MRTX849) in NSCLC With KRASG12C Mutation From a Phase 1/2 Study
Presentation — EORTC-NCI-AACR 32nd Symposium 2020
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRASG12C Mutation
Poster — AACR Part II 2020
The anti-tumor activity of the KRASG12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models
Presentation — AACR Part II 2020
Drug-Anchored in vitro and in vivo CRISPR Screens to Identify Targetable Vulnerabilities and Modifiers of Response to MRTX849 in KRASG12C-Mutant Models
Research Article — Journal of Medicinal Chemistry, April 2020
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Research Article — Journal of Internal Medicine, March 2020
Targeting KRASG12C‐Mutant Cancer with a Mutation‐Specific Inhibitor
Poster — 2019 AACR-NCI-EORTC Conference
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment
Poster — 2019 AACR-NCI-EORTC Conference
Discovery and Preclinical Development of MRTX849 A Mutation-Selective KRASG12C Inhibitor
Presentation — 2019 AACR-NCI-EORTC Conference
Pre-Clinical Data Presentation – Christensen – October 2019
Presentation — 2019 AACR-NCI-EORTC Conference
Clinical Data Presentation – Janne – October 2019
Research Article — Cancer Discovery, Oct. 2019
Christensen, J.G. et al, The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients, Cancer Discov October 28 2019 DOI: 10.1158/2159-8290.CD-19-1167
Poster — 2019 ASCO Conference
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRASG12C Mutation
Poster — 2019 AACR Conference
Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257, a Novel KRASG12C Mutant-Selective Small Molecule Inhibitor
Poster — 2018 AACR-RAS Conference
Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRASG12C Inhibitor with Oral Activity in Animal Models of Cancer
Poster — 2018 AACR-RAS Conference
Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257: A Prototype Selective Inhibitor of KRASG12C
Poster — ACS 2018
Structure-Based Drug Discovery of a Selective, Covalent KRASG12C Inhibitor with Oral Activity in Animal Models of Cancer